{"product_id":"cah-vrio-analysis","title":"Cardinal Health, Inc. (CAH): VRIO Analysis [June-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eThis ready-made VRIO Analysis gives you a clear, research-based view of Cardinal Health, Inc. through \u003cstrong\u003e9\u003c\/strong\u003e core resources and capabilities, showing where its advantages are \u003cstrong\u003esustained\u003c\/strong\u003e or \u003cstrong\u003etemporary\u003c\/strong\u003e. You’ll learn how scale in the \u003cstrong\u003eU.S. pharmaceutical distribution Big Three\u003c\/strong\u003e, hub expansion, robotics, Nuclear and Precision Health, ContinuCare, Advanced Diabetes Supply, AI tools, and disciplined capital allocation shape value, rarity, inimitability, and organization for coursework, case studies, presentations, and business research.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: First Core Capabilities \/ Resources\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e FY2024 net sales. \u003cstrong\u003e2\u003c\/strong\u003e operating segments. \u003cstrong\u003e3\u003c\/strong\u003e major U.S. pharmaceutical distributors.\u003c\/p\u003e\n\n\u003ch3\u003eCore Capabilities \/ Resources\u003c\/h3\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 net sales: \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOperating segments: \u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMajor U.S. pharmaceutical distributors: \u003cstrong\u003e3\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Factor\u003c\/th\u003e\n\u003cth\u003eReal-Life Data\u003c\/th\u003e\n\u003cth\u003eCompetitive Effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e FY2024 net sales\u003c\/td\u003e\n\u003ctd\u003eMoves very large prescription and medical supply volume through the network.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e major U.S. pharmaceutical distributors\u003c\/td\u003e\n\u003ctd\u003eScale is rare in a concentrated distribution market.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments and nationwide logistics reach\u003c\/td\u003e\n\u003ctd\u003eHard to copy because scale, compliance, and contracts take years.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments supporting distribution scale\u003c\/td\u003e\n\u003ctd\u003eBuilt to capture value from volume, routing, and operating discipline.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eScale and market structure support long-run advantage.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eFY2024 net sales were \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e, showing the scale needed to move massive prescription volumes efficiently.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe U.S. pharmaceutical distribution market is concentrated among \u003cstrong\u003e3\u003c\/strong\u003e major distributors, which makes this scale rare.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eMatching a \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e distribution platform is difficult because it requires contracts, logistics infrastructure, and compliance systems.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eCardinal Health is organized through \u003cstrong\u003e2\u003c\/strong\u003e operating segments, which supports capture of distribution economics at national scale.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Second Core Capabilities \/ Resources\n\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO element\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue; \u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/td\u003e\n\u003ctd\u003eDiversified revenue across hospitals, clinics, and consumer-health fulfillment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments at this scale\u003c\/td\u003e\n\u003ctd\u003eIntegrated logistics and warehousing capacity is moderately rare\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCostly and time-consuming to replicate because of facilities, automation, and customer relationships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHub expansion and robotics investments show alignment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvantage is not durable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e execution and automation focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Third Core Capabilities \/ Resources\u003c\/h2\u003e\n\u003cp\u003eCardinal Health’s nuclear medicine and precision-health capability is a sustained advantage because it depends on regulated isotope sourcing, specialized facilities, and company-wide scale. Fiscal 2024 revenue was \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e, which gives the business funding support that smaller rivals usually cannot match.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO factor\u003c\/th\u003e\n    \u003cth\u003eReal-life data\u003c\/th\u003e\n    \u003cth\u003eWhy it matters\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue; oncology, urology, and advanced therapy growth supported by radiopharmaceutical and precision-health capability\u003c\/td\u003e\n    \u003ctd\u003eScale helps fund specialized supply, logistics, and clinical infrastructure\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eDomestic Actinium-225 and nuclear medicine capability\u003c\/td\u003e\n    \u003ctd\u003eSpecialized isotope access is not widely available\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eRegulation, technical know-how, isotope sourcing, specialized facilities\u003c\/td\u003e\n    \u003ctd\u003eThese barriers raise time, cost, and execution risk for competitors\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eLeadership has pivoted toward Nuclear and Precision Health\u003c\/td\u003e\n    \u003ctd\u003eThe resource is aligned with strategy, capital, and operating focus\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eRare and hard-to-copy capabilities are being actively used inside the company\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThis resource supports higher-margin growth tied to oncology, urology, and advanced therapy. The company’s \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue base matters because nuclear medicine and precision health need capital, logistics, and compliance spending.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eDomestic Actinium-225 capability is rare, and nuclear medicine capabilities are specialized. That makes the resource more valuable in a market where supply access and clinical execution are constrained.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCompetitors face regulation, technical know-how, isotope sourcing, and specialized facilities. Those barriers slow replication and increase the odds of failure.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eLeadership has explicitly pivoted toward Nuclear and Precision Health.\u003c\/li\u003e\n  \u003cli\u003eThe company’s scale at \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue supports execution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Fourth Core Capabilities \/ Resources\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e and \u003cstrong\u003e38.4 million\u003c\/strong\u003e point to scale and recurring diabetes-related demand in fiscal 2024.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue and \u003cstrong\u003e97.6 million\u003c\/strong\u003e U.S. adults with prediabetes support recurring home-based care and diabetes supply fulfillment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e38.4 million\u003c\/strong\u003e U.S. people with diabetes\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e97.6 million\u003c\/strong\u003e U.S. adults with prediabetes\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e3\u003c\/strong\u003e linked channels, ContinuCare, Advanced Diabetes Supply, and partner channels, make the referral-to-fulfillment setup uncommon.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO factor\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eReal-life reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContinuCare, Advanced Diabetes Supply, partner channels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal 2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemand base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S. people with diabetes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHard to copy quickly because it depends on the \u003cstrong\u003e2024\u003c\/strong\u003e Advanced Diabetes Supply Group acquisition and payer\/provider integration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e acquisition timing\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e channel linkage points\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e38.4 million\u003c\/strong\u003e diabetes patients as the demand pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eExecution is organized through \u003cstrong\u003e3\u003c\/strong\u003e channels and a \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue base.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Fifth Core Capabilities \/ Resources\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eCardinal Health reported \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e in fiscal 2024 revenue. At that scale, a \u003cstrong\u003e0.1%\u003c\/strong\u003e improvement equals \u003cstrong\u003e$226.8 million\u003c\/strong\u003e, so better inventory accuracy, risk prediction, pricing insight, and productivity can have material impact.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eEnterprise-scale analytics linked to real-time distribution data is moderately rare in health care distribution. Cardinal Health operates through \u003cstrong\u003e2\u003c\/strong\u003e operating segments, which makes integrated data more valuable when it is used across the business.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO step\u003c\/th\u003e\n    \u003cth\u003eReal-life data point\u003c\/th\u003e\n    \u003cth\u003eAnalytical effect\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/td\u003e\n    \u003ctd\u003eSmall efficiency gains scale quickly\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/td\u003e\n    \u003ctd\u003eIntegrated data use is harder to match at enterprise scale\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue base\u003c\/td\u003e\n    \u003ctd\u003eSystems are easier to copy than proprietary data integration\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eEnterprise-wide deployment across supply chain and specialty businesses\u003c\/td\u003e\n    \u003ctd\u003eSupports execution at scale\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eValue exists, but rivals can build similar tools over time\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe tools are easier to copy than physical assets, but harder to match when they depend on proprietary transaction data and system integration across a \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue platform.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes. Cardinal Health’s scale supports organized deployment across supply chain and specialty businesses, which is the key requirement for turning analytics into operating results.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue base\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e operating segments\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$226.8 million\u003c\/strong\u003e equals \u003cstrong\u003e0.1%\u003c\/strong\u003e of fiscal 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Sixth Core Capabilities \/ Resources\n\u003c\/h2\u003e\n\u003cp\u003eCardinal Health is one of \u003cstrong\u003e3\u003c\/strong\u003e dominant U.S. pharmaceutical distributors and reported fiscal 2024 revenue of \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eYes; a \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue base and a \u003cstrong\u003e3\u003c\/strong\u003e-firm market structure strengthen bargaining power, customer retention, and resilience.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e dominant U.S. pharmaceutical distributors\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eVery rare; only \u003cstrong\u003e3\u003c\/strong\u003e firms dominate U.S. pharmaceutical distribution.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eVery difficult; a new entrant would have to compete in a \u003cstrong\u003e3\u003c\/strong\u003e-player structure and match Cardinal Health’s scale.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eYes; Cardinal Health is positioned to monetize this structure through scale and contracts.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Element\u003c\/th\u003e\n    \u003cth\u003eReal-Life Data\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eStrategic Effect\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e dominant U.S. distributors; \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eSupports bargaining power and retention\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e dominant firms\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eLimited number of comparable players\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e-player market structure\u003c\/td\u003e\n    \u003ctd\u003eVery difficult\u003c\/td\u003e\n    \u003ctd\u003eHigh entry barriers\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e fiscal 2024 revenue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eScale and contracts support monetization\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eRare and hard to copy\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Seventh Core Capabilities \/ Resources\u003c\/h2\u003e\n\u003cp\u003eCardinal Health’s strongest VRIO signal here is \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e in fiscal 2024 revenue backed by \u003cstrong\u003e53\u003c\/strong\u003e years of operating history since \u003cstrong\u003e1971\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e1971\u003c\/strong\u003e; \u003cstrong\u003e53\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e53\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO element\u003c\/th\u003e\n    \u003cth\u003eReal-life data\u003c\/th\u003e\n    \u003cth\u003eNumber\u003c\/th\u003e\n    \u003cth\u003eStatus\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eFiscal 2024 revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eFounding year\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e1971\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eOperating history in 2024\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e53\u003c\/strong\u003e years\u003c\/td\u003e\n    \u003ctd\u003eHard to imitate\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eReporting segments\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive advantage\u003c\/td\u003e\n    \u003ctd\u003eVRIO result\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Eight Core Capabilities \/ Resources\n\u003c\/h2\u003e\n\u003cp\u003eFY2024 revenue was \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e, Cardinal Health had \u003cstrong\u003e2\u003c\/strong\u003e reportable segments, and Advanced Diabetes Supply Group was acquired for about \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCore capability \/ resource\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eRarity\u003c\/th\u003e\n\u003cth\u003eImitability\u003c\/th\u003e\n\u003cth\u003eOrganization\u003c\/th\u003e\n\u003cth\u003eCompetitive advantage\u003c\/th\u003e\n\u003cth\u003eReal-life evidence\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution network scale\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier purchasing leverage\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e reportable segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and compliance infrastructure\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eSolaris Health \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition integration capability\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAdvanced Diabetes Supply Group about \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio shift capability\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e reportable segments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer and contract management\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eFY2024 revenue \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData and operating systems\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eSolaris Health \u003cstrong\u003e2024\u003c\/strong\u003e; Advanced Diabetes Supply Group \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital allocation and execution\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eModerately rare\u003c\/td\u003e\n\u003ctd\u003eHard\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eCardinal Health, Inc. - VRIO Analysis: Ninth Core Capabilities \/ Resources\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e in FY2024 net sales gave Cardinal Health the cash base to fund dividends, buybacks, capex, debt reduction, and strategic investments without destabilizing operations.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Test\u003c\/th\u003e\n\u003cth\u003eReal-Life Number\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY2024 net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShare repurchase authorization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest full-year reference point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e of revenue is not rare by itself; disciplined capital allocation at this scale is more valuable than the scale alone.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e of repurchase capacity is easy to copy in theory, but harder to sustain without Cardinal Health’s FY2024 cash generation and balance-sheet control.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eOngoing repurchases and dividend payments in FY2024 show execution around a \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e operating base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.0 billion\u003c\/strong\u003e share repurchase authorization\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$226.8 billion\u003c\/strong\u003e FY2024 net sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e months ended \u003cstrong\u003eJune 30, 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e at the \u003cstrong\u003e$226.8 billion\u003c\/strong\u003e revenue scale.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516130975893,"sku":"cah-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/cah-vrio-analysis.png?v=1740157375","url":"https:\/\/dcf-model.com\/pt\/products\/cah-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}